Cargando…

Innovations in tuberculosis diagnostics: How far are we from reaching our goal?

Detalles Bibliográficos
Autores principales:	Varma-Basil, Mandira, Bose, Mridula
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2019
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798617/ https://www.ncbi.nlm.nih.gov/pubmed/31571624 http://dx.doi.org/10.4103/ijmr.IJMR_537_19

Ejemplares similares

Comparative Genetic Association Analysis of Human Genetic Susceptibility to Pulmonary and Lymph Node Tuberculosis
por: , Abhimanyu, et al.
Publicado: (2023)

Molecular epidemiology of tuberculosis: Opportunities & challenges in disease control
por: Varma-Basil, Mandira, et al.
Publicado: (2017)

Dilemmas with ethionamide susceptibility testing of Mycobacterium tuberculosis: A microbiologist & physician's nightmare
por: Varma-Basil, Mandira, et al.
Publicado: (2015)

Female genital tract tuberculosis: How long will it elude diagnosis?
por: Bose, Mridula
Publicado: (2011)

Subtle mutation, far-reaching effects
por: Apell, Hans-Jürgen
Publicado: (2017)

Goal-directed or goal-misdirected - how should we interpret the literature?
por: Roche, Anthony M, et al.
Publicado: (2010)

Correlation of drug resistance with single nucleotide variations through genome analysis and experimental validation in a multi-drug resistant clinical isolate of M. tuberculosis
por: Bhattacharyya, Kausik, et al.
Publicado: (2020)

Rodent models of postherpetic neuralgia: How far have we reached?
por: Ou, Mingxi, et al.
Publicado: (2023)

How far are we from viral hepatitis elimination service coverage targets?
por: Hutin, Yvan J‐F, et al.
Publicado: (2018)

Goal directed therapy: how long can we wait?
por: Gordon, Anthony C, et al.
Publicado: (2005)

Potential impact of efflux pump genes in mediating rifampicin resistance in clinical isolates of Mycobacterium tuberculosis from India
por: Narang, Anshika, et al.
Publicado: (2019)

“New Users” Are Confusing Our Counting: Reaching Consensus on How to Measure “Additional Users” of Family Planning
por: Dasgupta, Aisha, et al.
Publicado: (2017)

Legislation and current developments in adverse drug reaction reporting in Mongolia: how far are we?
por: Zulzaga, Zuzaan, et al.
Publicado: (2021)

Unlocking the microbial studies through computational approaches: how far have we reached?
por: Kumar, Rajnish, et al.
Publicado: (2023)

Inotropes in goal-directed therapy: Do we need 'goals'?
por: Futier, Emmanuel, et al.
Publicado: (2010)

Single nucleotide polymorphism in the genes of mce1 and mce4 operons of Mycobacterium tuberculosis: analysis of clinical isolates and standard reference strains
por: Pasricha, Rashmi, et al.
Publicado: (2011)

Registration, Evaluation, and Authorization of Chemicals (REACH) Is but the First Step–How Far Will It Take Us? Six Further Steps to Improve the European Chemicals Legislation
por: Rudén, Christina, et al.
Publicado: (2010)

Sixth Africa malaria day in 2006: how far have we come after the Abuja Declaration?
por: Rugemalila, Joas B, et al.
Publicado: (2006)

Sustainable Elimination (Zero Cases) of Sleeping Sickness: How Far Are We from Achieving This Goal?
por: Akazue, Pearl Ihuoma, et al.
Publicado: (2019)

How far will we need to go to reach HIV-infected people in rural South Africa?
por: Wilson, David P, et al.
Publicado: (2007)

Cost-Effective Pharmacologic Therapies to Treat Chronic Hepatitis B: How Far Have We Really Come?
por: Holbrook, Michelle
Publicado: (2008)

Toward Precision Medicine: How Far Is the Goal?
por: Ravegnini, Gloria, et al.
Publicado: (2016)

Commentary: Presumed tubercular posterior scleritis - What is our understanding so far?
por: Agarwal, Aniruddha
Publicado: (2019)

Aquaporins as diagnostic and therapeutic targets in cancer: How far we are?
por: Wang, Jian, et al.
Publicado: (2015)

How far are we? National preparedness and response capacities for emerging infectious disease outbreaks in the WHO Eastern Mediterranean Region
por: Al Ariqi, Lubna, et al.
Publicado: (2022)

Treating juvenile idiopathic arthritis to target: what is the optimal target definition to reach all goals?
por: Schoemaker, Casper G., et al.
Publicado: (2020)

Developing a national pharmaceutical research strategy in Lebanon: opportunities to bridge the gaps and reach the goals
por: Akel, Marwan, et al.
Publicado: (2022)

Will we reach the Sustainable Development Goals target for tuberculosis in the European Union/European Economic Area by 2030?
por: Merk, Hanna, et al.
Publicado: (2019)

2000 to 2015: How Far Have We Progressed in Achieving the Health Related Millennium Development Goals?
por: Shrivastava, Saurabh RamBihariLal, et al.
Publicado: (2016)

How far has robot-assisted partial nephrectomy reached?
por: Lee, Chung Un, et al.
Publicado: (2023)

How Safe Is Our Food?
por: Morris, J. Glenn
Publicado: (2011)

Pharmacists and telemedicine: an innovative model fulfilling Sustainable Development Goals (SDGs)
por: Bukhari, Nadia, et al.
Publicado: (2021)

Should we modulate the neonatal microbiome and what should be the goal?
por: van Best, Niels, et al.
Publicado: (2022)

Towards goal-directed therapy of hepatorenal syndrome: we have the tools but we need the trials
por: Mookerjee, Rajeshwar P, et al.
Publicado: (2008)

COVID‐19 infection in CVID patients: What we know so far
por: Weifenbach, Niels, et al.
Publicado: (2021)

How old are the oldest Homo sapiens in Far East Asia?
por: Hublin, Jean-Jacques
Publicado: (2021)

Revisiting IL-13 blockade: can we reach the wonderland the inhaled way?
por: Papaioannou, Andriana I., et al.
Publicado: (2018)

Fast-track hip and knee arthroplasty – have we reached the goal?
por: Wainwright, Thomas W, et al.
Publicado: (2019)

Reaching the sustainable development goals through healthy environments: are we on track?
por: Racioppi, F, et al.
Publicado: (2020)

Global end-diastolic volume an emerging preload marker vis-a-vis other markers - Have we reached our goal?
por: Kapoor, P. M, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_6jri6qoog3fs4d1rnh2n9vfeih